MedTrace Logo

Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis

NCT04944251 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-06-29

No results posted yet for this study

Summary

ABSTRACT

Objective:

The investigators aimed to determine the effect of regular exercise on aerobic capacity, strength values, and plasma levels of nerve growth factor (NGF) and Neurotrophin-3 (NT-3) in patients with multiple sclerosis (MS), and investigate its effects on MS symptoms including cognitive impairment, fatigue, balance disorders and quality of life.

Methods:

Forty-three relapsing-remitting MS (RRMS) patients with an EDSS score of 4 or less participated in the study. Participants were divided into 3 groups as aerobic exercise, strength exercise and control groups. The patients in the exercise groups had exercise programs 3 days a week, for 3 months. Aerobic capacity (maximum VO2 value), strength measurements and balance tests were done, and NGF and NT-3 plasma levels were analyzed in all participants at the beginning and end of the study. MSQoL54 quality of life, fatigue impact scale (FIS), Pittsburgh Sleep Quality Index (PSQI) and BICAMS scale were applied to evaluate cognitive functions.

Conditions

Interventions

BEHAVIORAL

Regular Exercise

the third month, for 30 minutes or 1 hour, 3 days a week

Sponsors & Collaborators

  • Ege University

    lead OTHER

Principal Investigators

  • Mehmet ACIK, Dr · Ege University

  • Seckin Senisik, Ass. Prof. · Ege University

  • Nur Yuceyar, Professor · Ege University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-12-01
Completion
2020-01-19

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04944251 on ClinicalTrials.gov